Viola Franke

524 total citations
18 papers, 263 citations indexed

About

Viola Franke is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Viola Franke has authored 18 papers receiving a total of 263 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 7 papers in Genetics and 6 papers in Molecular Biology. Recurrent topics in Viola Franke's work include Cutaneous Melanoma Detection and Management (11 papers), Virus-based gene therapy research (7 papers) and CAR-T cell therapy research (6 papers). Viola Franke is often cited by papers focused on Cutaneous Melanoma Detection and Management (11 papers), Virus-based gene therapy research (7 papers) and CAR-T cell therapy research (6 papers). Viola Franke collaborates with scholars based in Netherlands, Australia and United States. Viola Franke's co-authors include Alexander C. J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Bart A. van de Wiel, W. Martin C. Klop, Bernies van der Hiel, Sylvia ter Meulen, Max F. Madu, Katarzyna Jóźwiak and John B.A.G. Haanen and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Viola Franke

18 papers receiving 262 citations

Peers

Countries citing papers authored by Viola Franke

Since Specialization

Citations

This map shows the geographic impact of Viola Franke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Viola Franke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Viola Franke more than expected).

Fields of papers citing papers by Viola Franke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Viola Franke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Viola Franke. The network helps show where Viola Franke may publish in the future.

Co-authorship network of co-authors of Viola Franke

This figure shows the co-authorship network connecting the top 25 collaborators of Viola Franke. A scholar is included among the top collaborators of Viola Franke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Viola Franke. Viola Franke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial. 2023 ·Journal of Clinical Oncology ·(unknown), Winan J. van Houdt, (unknown), Viola Franke, Maartje W. Rohaan, (unknown), Charlotte L. Zuur, W. Martin C. Klop, Bart A. van de Wiel, Anke Kuijpers, (unknown), Johannes V. van Thienen, John B.A.G. Haanen, Alexander Christopher Jonathan Van Akkooi	9
2	Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective 2022 ·Journal of Immunotherapy ·Viola Franke, (unknown), Bernies van der Hiel, Bart A. van de Wiel, Michel W.J.M. Wouters, Winan J. van Houdt, Alexander C. J. van Akkooi	7
3	Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial 2022 ·BMC Cancer ·Maartje W. Rohaan, (unknown), Viola Franke, (unknown), Sofie Wilgenhof, Vincent van der Noort, Alexander C. J. van Akkooi, John B.A.G. Haanen	21
4	Talimogene laherparepvec monotherapy for head and neck melanoma patients 2022 ·Melanoma Research ·Viola Franke, (unknown), W. Martin C. Klop, Charlotte L. Zuur, (unknown), Bernies van der Hiel, Bart A. van de Wiel, Michel W.J.M. Wouters, Winan J. van Houdt, Alexander C. J. van Akkooi	8
5	T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model 2021 ·Cancer Immunology Immunotherapy ·(unknown), Viola Franke, Charlotte L. Zuur, W. Martin C. Klop, Bernies van der Hiel, Bart A. van de Wiel, Michel W.J.M. Wouters, Yvonne Schrage, Winan J. van Houdt, Alexander C. J. van Akkooi	20
6	Complete response to talimogene laherparepvec in a primary acral lentiginous melanoma 2020 ·Melanoma Research ·Viola Franke, (unknown), Jacqueline E. van der Wal, Alexander C. J. van Akkooi	5
7	Challenges in sentinel node pathology in the era of adjuvant treatment 2020 ·Journal of Surgical Oncology ·Viola Franke, Max F. Madu, Carolien Bierman, W. Martin C. Klop, Winan J. van Houdt, Michel W.J.M. Wouters, Bart A. van de Wiel, Alexander C. J. van Akkooi	4
8	A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries 2020 ·Advances in Therapy ·Alexander C. J. van Akkooi, Sebastian Haferkamp, Sophie Papa, Viola Franke, Andreas Pinter, Carsten Weishaupt, Margit A. Huber, Carmen Loquai, Erika Richtig, (unknown), Katarina Öhrling, Karly S. Louie, Peter Mohr	15
9	External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment? 2019 ·Melanoma Research ·Max F. Madu, Viola Franke, Bart A. van de Wiel, W. Martin C. Klop, Katarzyna Jóźwiak, Winan J. van Houdt, Michel W.J.M. Wouters, Alexander C. J. van Akkooi	13
10	Challenges in sentinel node (SN) pathology in the era of adjuvant treatment: The risk of over and undertreatment stress the need for expert pathology review. 2019 ·Journal of Clinical Oncology ·Viola Franke, Max F. Madu, Carolien Bierman, W. Martin C. Klop, Winan J. van Houdt, Michel W.J.M. Wouters, Bart A. van de Wiel, Alexander Christopher Jonathan Van Akkooi	1
11	The extent of surgery for stage III melanoma: how much is appropriate? 2019 ·The Lancet Oncology ·Viola Franke, Alexander C. J. van Akkooi	19
12	Re-introduction of T-VEC monotherapy in recurrent stage IIIB/C-IVM1a melanoma is effective 2019 ·Annals of Oncology ·Viola Franke, (unknown), Bernies van der Hiel, Bart A. van de Wiel, Michel W.J.M. Wouters, Winan J. van Houdt, Alexander C. J. van Akkooi	1
13	High response rates for T‐VEC in early metastatic melanoma (stage IIIB/C‐IVM1a) 2019 ·International Journal of Cancer ·Viola Franke, (unknown), W. Martin C. Klop, Bernies van der Hiel, Bart A. van de Wiel, Sylvia ter Meulen, Michel W.J.M. Wouters, Winan J. van Houdt, Alexander C. J. van Akkooi	66
14	Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma 2019 ·British journal of surgery ·(unknown), Viola Franke, Elisa A. Rozeman, Bart A. van de Wiel, Annemarie Bruining, Michel W.J.M. Wouters, Winan J. van Houdt, B. ten Haken, S.H. Muller, Carolien Bierman, Theo J. M. Ruers, Christian U. Blank, Alexander C. J. van Akkooi	27
15	Validation of a Nomogram for Non-sentinel Node Positivity in Melanoma Patients, and Its Clinical Implications: A Brazilian–Dutch Study 2018 ·Annals of Surgical Oncology ·Eduardo Bertolli, Viola Franke, Vinícius F. Calsavara, Mariana Petaccia de Macêdo, Clóvis Antônio Lopes Pinto, Winan J. van Houdt, Michel W.J.M. Wouters, João Pedreira Duprat Neto, Alexander C. J. van Akkooi	12
16	Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes 2018 ·British journal of surgery ·D. Verver, David van Klaveren, Viola Franke, Alexander C. J. van Akkooi, Piotr Rutkowski, Ulrich Keilholz, Alexander M.M. Eggermont, Tamar Nijsten, Dirk J. Grünhagen, Cornelis Verhoef	24
17	External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC): Effect of adding EORTC sentinel node (SN) tumor burden criteria on prognostic accuracy in stage III. 2018 ·Journal of Clinical Oncology ·Max F. Madu, Viola Franke, B. van de Wiel, W. Martin C. Klop, Katarzyna Jóźwiak, Michel W.J.M. Wouters, Alexander Christopher Jonathan Van Akkooi	9
18	Exogenous Cushing's syndrome due to a Chinese herbalist’s prescription of ointment containing dexamethasone 2017 ·BMJ Case Reports ·Viola Franke, (unknown), Inès A. von Rosenstiel, M.J.E. Walenkamp	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact